SAN DIEGO, April 8, 2014 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) today announced that two
scientific poster presentations on the pharmacology of PEGPH20 will
be made at the American Association for Cancer Research (AACR)
annual meeting being held in San
Diego. The first presentation includes preclinical data
showing that treatment of tumors with PEGPH20 enhances the action
of immune-based cancer therapy such as monoclonal antibodies
(mAbs). The second presentation includes preclinical data showing
that overproduction of hyaluronan (HA) in tumor stroma enhances
tumor growth, and that PEGPH20, as a single agent, suppresses
growth of HA-rich tumors and inhibits early events of epithelial to
mesenchymal transition (EMT), a key process involved in metastasis.
PEGPH20 is an investigational PEGylated form of rHuPH20 under
development by Halozyme, which degrades the hyaluronan coating that
may provide a supportive environment in many solid tumors.
"These findings advance our understanding of the pharmacology of
PEGPH20 and offer new scientific insight into ways to utilize
PEGPH20 to potentially improve cancer therapies," stated
H. Michael Shepard, Ph.D., Vice
President and Chief Scientific Officer. "These data show in
preclinical models the potential antimetastatic effects of PEGPH20,
as well as PEGPH20's ability to work in combination with
chemotherapy and targeted agents, like monoclonal
antibodies."
ACR Poster Presentation Details
Title: "Pegylated Recombinant Human Hyaluronidase PH20
(PEGPH20) Enhances Cetuximab Efficacy in BxPC-3/HAS3 Human
Pancreatic Cancer Xenografts"
Abstract #: 3646, April 8,
2014, 8:00AM - 12:00PM PDT
Location: Hall A-E, Poster Section 26
Summary: HA accumulation creates a coating that surrounds
certain solid tumor cells and protects them from attack by
therapeutic antibodies. HA-overexpressed PDA tumors treated with
PEGPH20 enhance the immune activating antibodies and anti-tumor
activity of mAbs, such as Cetuximab.
Title: "Extracellular Hyaluronan Accumulation by
Hyaluronan Synthase 3 Promotes
Pancreatic Cancer Growth and Modulates Tumor Microenvironment via
Epithelial-Mesenchymal Transition"
Abstract #: 4844, April 9,
2014, 8:00AM - 12:00PM PDT
Location: Hall A-E, Poster Section 2
Summary: These data demonstrate that HA accumulation by
hyaluronan synthase 3 (HAS3) enzyme favors pancreatic cancer growth
in animal models. In addition, PEGPH20, as a single agent, inhibits
tumor growth and reduces early events associated with EMT.
About Halozyme
Halozyme Therapeutics is a biopharmaceutical company
dedicated to developing and commercializing innovative products
that advance patient care. With a diversified portfolio of enzymes
that target the extracellular matrix, the Company's research
focuses primarily on a family of human enzymes, known as
hyaluronidases, which increase the dispersion and absorption of
biologics, drugs and fluids. Halozyme's pipeline addresses
therapeutic areas, including oncology, diabetes and dermatology
that have significant unmet medical need today. The Company markets
Hylenex® recombinant (hyaluronidase human
injection) and has partnerships with Roche, Pfizer and
Baxter. Halozyme is headquartered
in San Diego, CA. For more information on how we are
innovating, please visit our corporate website at
www.halozyme.com.
Safe Harbor Statement
In addition to historical information, the statements set forth
above include forward-looking statements (including, without
limitation, statements concerning the possible activity, benefits
and attributes of PEGPH20, the possible method of action of
PEGPH20, its potential application to improve cancer therapies and
statements concerning future actions relating to the development of
PEGPH20) that involve risk and uncertainties that could cause
actual results to differ materially from those in the
forward-looking statements. The forward-looking statements are
typically, but not always, identified through use of the words
"believe," "enable," "may," "will," "could," "intends," "estimate,"
"anticipate," "plan," "predict," "probable," "potential,"
"possible," "should," "continue," and other words of similar
meaning. Actual results could differ materially from the
expectations contained in forward-looking statements as a result of
several factors, including unexpected expenditures and costs,
unexpected results or delays in development and regulatory review,
regulatory approval requirements, unexpected adverse events and
competitive conditions. These and other factors that may result in
differences are discussed in greater detail in the Company's Annual
Report on Form 10-K filed with the Securities and Exchange
Commission on February 28, 2014.
Investor Contact:
Schond Greenway
Halozyme Therapeutics
858-704-8352
ir@halozyme.com
Media Contact:
Denise
Powell
510-703-9491
dpowell@brewlife.com
Logo -
http://photos.prnewswire.com/prnh/20100302/LA63139LOGO
SOURCE Halozyme Therapeutics, Inc.